Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tysabri Court Loss Gets Elan Into Another Fine Mess

Executive Summary

On July 21, Elan CEO Kelly Martin kicked off his company's half-year earnings call with lots of good news, something rare for the Irish biotech in the past few years

You may also be interested in...



Elan Moves Ahead With J&J Deal, But Does Biogen Really Approve?

Is it over? Elan Corp. and Johnson & Johnson said Sept. 17 they successfully closed their deal to share Alzheimer disease programs

Elan Moves Ahead With J&J Deal, But Does Biogen Really Approve?

Is it over? Elan Corp. and Johnson & Johnson said Sept. 17 they successfully closed their deal to share Alzheimer disease programs

Judge Says Elan's J&J Deal Violates Tysabri Contract, Handing Biogen A Victory

Biogen Idec's lawyers took heat all day Thursday from a federal judge, but in the end she ruled in their favor. Now, Elan has 23 days to fix the breach.

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel